Publications

publications by categories in reversed chronological order.

2025

  1. Repertoire and clinical hierarchy of AR locus alterations in castration-resistant prostate cancer
    Tuomo Virtanen, Edmond M. Kwan, Karan Parekh, Jack V. W. Bacon, Chia-Chi Flora Huang, Ivan P. L. Yu, Lauri Ryyppö, Cecily Q. Bernales, Gráinne Donnellan, Chris Tam, Joonatan Sipola, Jussi Nikkola, Gillian Vandekerkhove, Sofie H. Tolmeijer, Konsta Kukkonen, Adelia, Bernhard J. Eigl, Daygen L. Finch, Richard Gagnon, Yomna Takieldeen, Edward Hardy, Daniel J. Khalaf, C. Kollmannsberger, Jean-Michel Lavoie, Corinne Maurice-Dror, Stacy Miller, Lucia Nappi, Krista Noonan, Sunil Parimi, Anna Riminchan, Elsa Sartori-Mueller, Maryam Soleimani, Joanna Vergidis, Muhammad Zulfiqar, Aaron Hansen, Sebastien J. Hotte, Mariam Jafri, Michael Kolinsky, Som D. Mukherjee, Michael Ong, April A. N. Rose, Wilson Tu, Eric Winquist, Andries M. Bergman, Kim Zande, Wilbert Zwart, Niven Mehra, Nielka P. Erp, Jimmy L. Zhao, Dana E. Rathkopf, Christopher E. Barbieri, David Quigley, Matti Nykter, Nathan A. Lack, Kim N. Chi, Matti Annala, and Alexander W. Wyatt
    Annals of Oncology, Oct 2025
    HTML
  2. Baited SELEX: Drug-Directed Selection of Aptamers to PSMA for In Vivo Targeting of Prostate Cancer Xenografts in Mice
    Kun Liu, Nicole Robinson, Emirhan Tekoglu, Jerome Lozada, Ivan Pak Lok Yu, Ruyin Astoria Tai, Dogancan Ozturan, Ugur Meric Dikbas, Nathan A. Lack, Michael E. Cox, Miles P. Mannas, Philip Cohen, S. Larry Goldenberg, and David M. Perrin
    Journal of the American Chemical Society, Oct 2025
    HTML
  3. The Androgen Receptor and MYC synergise to modulate the synthesis of Siglec-7 ligands in prostate cancer
    Adam Duxfield, Rebecca Garnham, Esme Hutton, Adam Dowle, Jamie Wills, Sara Luzzi, Ryan Nelson, Emma Lishman-Walker, Rianna Magee, Adriana Buskin, Anastasia C. Hepburn, Emirhan Tekoglu, Kaidan Maloney-Friar, Fiona Frame, Norman Maitland, Ann Hedley, Holly Henderson, Benjamin McCullough, Bharat Gowardhan, Kanagasabai Sahadevan, Stuart McCracken, Luke Gaughan, Rakesh Heer, Craig N. Robson, Kelly Coffey, Nathan Lack, Nathalie Signoret, Martin Fascione, and Emma Scott
    bioRxiv, Oct 2025
    HTML
  4. Elucidating molecularly stratified single agent, and combination, therapeutic strategies targeting MCL1 for lethal prostate cancer
    Juan M. Jiménez-Vacas, Daniel Westaby, Ines Figueiredo, Alexis De Haven Brandon, Ana Padilha, Wei Yuan, George Seed, Denisa Bogdan, Bora Gurel, Claudia Bertan, Susana Miranda, Maryou Lambros, Antonio J. Montero-Hidalgo, Ilsa Coleman, Ivan Pak Lok Yu, Lorenzo Buroni, Wanting Zeng, Antje J. Neeb, Jon Welti, Jan Rekowski, Roberta Paravati, Florian Gabel, Nicole Pandell, Ana Ferreira, Mateus Crespo, Ruth Riisnaes, Souvik Das, Joe Taylor, Nick Waldron, Emily Hobern, Melanie Valenti, Jian Ning, Ilona Bernett, Kate Liodaki, Thomas Persse, Patricia Galipeau, Scott Wilkinson, Shana Y. Trostel, Fatima Karzai, Cindy H. Chau, Erica L. Beatson, Xiaohu Zhang, Carleen Klumpp-Thomas, Andreas Varkaris, Raul M. Luque, Amanda Swain, Florence Raynaud, Nathan A. Lack, Craig J. Thomas, Gavin Ha, William D. Figg, Marco Bezzi, Adam G. Sowalsky, Peter S. Nelson, Suzanne Carreira, Steven P. Balk, Johann S. Bono, and Adam Sharp
    Nature Communications, Oct 2025
    HTML
  5. Coregulators determine androgen receptor activity in prostate cancer
    Kerim Yavuz and Nathan A. Lack
    Bioscience Reports, Aug 2025
    HTML
  6. Comprehensive functional annotation of ESR1-driven enhancers in breast cancer reveals hierarchical activity independent of genomic and epigenomic contexts
    Yanis Zekri, Sebastian Gregoricchio, Elif Yapıcı, Chia-Chi Flora Huang, Tunç Morova, Umut Berkay Altıntaş, Gozde Korkmaz, Nathan A. Lack, and Wilbert Zwart
    Genome Research, Jun 2025
    HTML
  7. Longitudinal single-cell analysis reveals RUNX1T1 as an early driver in treatment-induced neuroendocrine transdifferentiation
    Yuchao Ni, Dong Lin, Mingchen Shi, Yen-Yi Lin, Hui Xue, Xin Dong, Liangliang Liu, Funda Sar, Rebecca Wu, Tunc Morova, Anne Haegert, Robert Bell, Xinyao Pang, Adam Classen, Yu Wang, Junru Chen, Stanislav Volik, Stéphane Le Bihan, Nathan Lack, Christopher Ong, Gang Wang, Hao Zeng, Colin Collins, and Yuzhuo Wang
    bioRxiv, May 2025
    HTML
  8. Longitudinal single-cell RNA sequencing of a neuroendocrine transdifferentiation model reveals transcriptional reprogramming in treatment-induced neuroendocrine prostate cancer
    Funda Sar, Hee Chul Chung, Yen-Yi Lin, Dong Lin, Tunc Morova, Anne Haegert, Stanislav Volik, Robert Bell, Stephane LeBihan, Dogancan Ozturan, Hui Xie, Xin Dong, Rebecca Wu, Jing Li, Hsing-Jien Kung, Martin E. Gleave, Nathan A. Lack, Yuzhuo Wang, and Colin C. Collins
    bioRxiv, Apr 2025
    HTML
  9. A chromatin-focused CRISPR screen identifies USP22 as a barrier to somatic cell reprogramming
    Gülben Gürhan, Kenan Sevinç, Can Aztekin, Mert Gayretli, Alperen Yılmaz, Abdullah Burak Yıldız, Elif Naz Ervatan, Tunç Morova, Elif Datlı, Oliver D. Coleman, Akane Kawamura, Nathan A. Lack, Hamzah Syed, and Tamer Önder
    Communications Biology, Mar 2025
    HTML
  10. B7-H3 as a Dual Clinically Relevant Checkpoint and Antibody Drug Conjugate Target Expressed Across Adenocarcinoma and Neuroendocrine Prostate Cancers
    Shivang Sharma, Nikita Mundhara, Emirhan Tekoglu, Adrianna Amaral, Tamara L. Lotan, Pan Gu, Jun Luo, Ezra G. Baraban, Nathan A. Lack, and Eugene Shenderov
    bioRxiv, Jan 2025
    HTML
  11. Increased nuclear factor I-mediated chromatin access drives transition to androgen receptor splice variant dependence in prostate cancer
    Larysa Poluben, Mannan Nouri, Jiaqian Liang, Shaoyong Chen, Andreas Varkaris, Betul Ersoy-Fazlioglu, Olga Voznesensky, Irene I. Lee, Xintao Qiu, Laura Cato, Ji-Heui Seo, Matthew L. Freedman, Adam G. Sowalsky, Nathan A. Lack, Eva Corey, Peter S. Nelson, Myles Brown, Henry W. Long, Joshua W. Russo, and Steven P. Balk
    Cell Reports, Jan 2025
    HTML
  12. Identification of selective SWI/SNF dependencies in enzalutamide-resistant prostate cancer
    Bengul Gokbayrak, Umut Berkay Altintas, Shreyas Lingadahalli, Tunc Morova, Chia-Chi Flora Huang, Betul Ersoy Fazlioglu, Ivan Pak Lok Yu, Batuhan M. Kalkan, Paloma Cejas, Sonia H. Y. Kung, Ladan Fazli, Akane Kawamura, Henry W. Long, Ceyda Acilan, Tamer T. Onder, Tugba Bagci-Onder, James T. Lynch, and Nathan A. Lack
    Communications Biology, Feb 2025
  13. AR-V7 condensates drive androgen-independent transcription in castration resistant prostate cancer
    Shabnam Massah, Nicholas Pinette, Jane Foo, Sumanjit Datta, Maria Guo, Robert Bell, Anne Haegert, Tahsin Emirhan Tekoglu, Mailyn Terrado, Stanislav Volik, Stephane Le Bihan, Jennifer M. Bui, Nathan A. Lack, Martin E. Gleave, Suhn K. Rhie, Colin C. Collins, Jörg Gsponer, and Nada Lallous
    bioRxiv, Jan 2025
    HTML
  14. Chromatin-focused genetic and chemical screens identify BRPF1 as a targetable vulnerability in Taxol-resistant triple-negative breast cancer
    Ozlem Yedier-Bayram, Ahmet Cingöz, Ebru Yilmaz, Ali Cenk Aksu, Beril Esin, Nareg Degirmenci, Ayşe Derya Cavga, Beyza Dedeoğlu, Buse Cevatemre, Hamzah Syed, Martin Philpott, Adam P. Cribbs, Udo Oppermann, Nathan A. Lack, Ceyda Acilan, Tamer T. Onder, and Tugba Bagci-Onder
    Experimental & Molecular Medicine, Jun 2025
    HTML
  15. Inference of transcriptional regulation from STARR-seq data
    Amin Safaeesirat, Hoda Taeb, Emirhan Tekoglu, Tunc Morova, Nathan A. Lack, and Eldon Emberly
    Physical Review E, Feb 2025
    HTML

2024

  1. Decoding the epigenetics and chromatin loop dynamics of androgen receptor-mediated transcription
    Umut Berkay Altıntaş, Ji-Heui Seo, Claudia Giambartolomei, Dogancan Ozturan, Brad J. Fortunato, Geoffrey M. Nelson, Seth R. Goldman, Karen Adelman, Faraz Hach, Matthew L. Freedman, and Nathan A. Lack
    Nature Communications, Nov 2024
    HTML
  2. Genomic and transcriptomic features of androgen receptor signaling inhibitor resistance in metastatic castration-resistant prostate cancer
    Xiaolin Zhu, Tatyanah Farsh, Daniël Vis, Ivan Yu, Haolong Li, Tianyi Liu, Martin Sjöström, Raunak Shrestha, Jeroen Kneppers, Tesa Severson, Meng Zhang, Arian Lundberg, Thaidy Moreno Rodriguez, Alana S. Weinstein, Adam Foye, Niven Mehra, Rahul R. Aggarwal, Andries M. Bergman, Eric J. Small, Nathan A. Lack, Wilbert Zwart, David A. Quigley, Michiel S. Heijden, and Felix Y. Feng
    Journal of Clinical Investigation, Aug 2024
    HTML
  3. Estrogen receptor 1 chromatin profiling in human breast tumors reveals high inter-patient heterogeneity with enrichment of risk SNPs and enhancer activity at most-conserved regions
    Stacey E.P. Joosten, Sebastian Gregoricchio, Suzan Stelloo, Elif Yapıcı, Chia-Chi Flora Huang, Kerim Yavuz, Maria Donaldson Collier, Tunç Morova, Umut Berkay Altintaş, Yongsoo Kim, Sander Canisius, Cathy B. Moelans, Paul J. Diest, Gozde Korkmaz, Nathan A. Lack, Michiel Vermeulen, Sabine C. Linn, and Wilbert Zwart
    Genome Research, May 2024
    HTML

2023

  1. 5‐Fluoro/(trifluoromethoxy)‐2‐indolinone derivatives with anti‐interleukin‐1 activity
    Özge Soylu‐Eter, Zekiye Şeyma Sevinçli, Betül Ersoy, Bahar Hasanusta, Uğur Gatfar, Nathan A. Lack, Burak Erman, Ahmet Gül, Hakan S. Orer, and Nilgün Karalı
    Archiv der Pharmazie, Oct 2023
    HTML
  2. Epigenetic-focused CRISPR/Cas9 screen identifies (absent, small, or homeotic)2-like protein (ASH2L) as a regulator of glioblastoma cell survival
    Ezgi Ozyerli-Goknar, Ezgi Yagmur Kala, Ali Cenk Aksu, Ipek Bulut, Ahmet Cingöz, Sheikh Nizamuddin, Martin Biniossek, Fidan Seker-Polat, Tunc Morova, Can Aztekin, Sonia H. Y. Kung, Hamzah Syed, Nurcan Tuncbag, Mehmet Gönen, Martin Philpott, Adam P. Cribbs, Ceyda Acilan, Nathan A. Lack, Tamer T. Onder, H. T. Marc Timmers, and Tugba Bagci-Onder
    Cell Communication and Signaling, Nov 2023
    HTML
  3. HOXB13 alters chromatin accessibility in prostate cancer through interactions with the SWI/SNF complex
    Shreyas Lingadahalli, Betul Ersoy Fazlioglu, Umut Berkay Altintas, Ahmet Cingoz, Emirhan Tekoglu, Ivan Pak Lok Yu, Ugur Meric Dikbas, Hans Andomat, Ibrahim Kulac, Tunc Morova, Kevin Xiao, Martin Gleave, Ladan Fazli, Paloma Cejas, Artem Cherkasov, Wilbert Zwart, Henry Long, Colin Collins, Tugba Bagci-Onder, and Nathan A. Lack
    bioRxiv, Sep 2023
    HTML
  4. Curcuphenol possesses an unusual histone deacetylase enhancing activity that counters immune escape in metastatic tumours
    Samantha L. S. Ellis, Sarah Dada, Lilian L. Nohara, Iryna Saranchova, Lonna Munro, Cheryl G. Pfeifer, Brett A. Eyford, Tunc Morova, David E. Williams, Ping Cheng, Nathan A. Lack, Raymond J. Andersen, and Wilfred A. Jefferies
    Frontiers in Pharmacology, Aug 2023
    HTML
  5. The “Ins and Outs” of Prostate Specific Membrane Antigen (PSMA) as Specific Target in Prostate Cancer Therapy
    Felipe Eltit, Nicole Robinson, Pak Lok Ivan Yu, Mitali Pandey, Jerome Lozada, Yubin Guo, Manju Sharma, Dogancan Ozturan, Laetitia Ganier, Eric Belanger, Nathan A. Lack, David M. Perrin, Michael E. Cox, and S. Larry Goldenberg
    Aug 2023
    HTML
  6. Specific cannabinoids revive adaptive immunity by reversing immune evasion mechanisms in metastatic tumours
    Sarah Dada, Samantha L. S. Ellis, Christi Wood, Lilian L. Nohara, Carola Dreier, Nicolas H. Garcia, Iryna Saranchova, Lonna Munro, Cheryl G. Pfeifer, Brett A. Eyford, Suresh Kari, Emmanuel Garrovillas, Giorgia Caspani, Eliana Al Haddad, Patrick W. Gray, Tunc Morova, Nathan A. Lack, Raymond J. Andersen, Larry Tjoelker, and Wilfred A. Jefferies
    Frontiers in Immunology, Feb 2023
    HTML

2022

  1. Optimized high-throughput screening of non-coding variants identified from genome-wide association studies
    Tunc Morova, Yi Ding, Chia-Chi F Huang, Funda Sar, Tommer Schwarz, Claudia Giambartolomei, Sylvan C Baca, Dennis Grishin, Faraz Hach, Alexander Gusev, Matthew L Freedman, Bogdan Pasaniuc, and Nathan A Lack
    Nucleic Acids Research, Dec 2022
    HTML
  2. Dynamic phase separation of the androgen receptor and its coactivators key to regulate gene expression
    Fan Zhang, Maitree Biswas, Shabnam Massah, Joseph Lee, Shreyas Lingadahalli, Samantha Wong, Christopher Wells, Jane Foo, Nabeel Khan, Helene Morin, Neetu Saxena, Sonia H Y Kung, Bei Sun, Ana Karla Parra Nu nez, Christophe Sanchez, Novia Chan, Lauren Ung, Umut Berkay Altintas, Jennifer M Bui, Yuzhuo Wang, Ladan Fazli, Htoo Zarni Oo, Paul S Rennie, Nathan A. Lack, Artem Cherkasov, Martin E Gleave, Jörg Gsponer, and Nada Lallous
    Nucleic Acids Research, Dec 2022
    HTML
  3. Extensive androgen receptor enhancer heterogeneity in primary prostate cancers underlies transcriptional diversity and metastatic potential
    Jeroen Kneppers, Tesa M. Severson, Joseph C. Siefert, Pieter Schol, Stacey E. P. Joosten, Ivan Pak Lok Yu, Chia-Chi Flora Huang, Tunc Morova, Umut Berkay Altintas, Claudia Giambartolomei, Ji-Heui Seo, Sylvan C. Baca, Isa Carneiro, Eldon Emberly, Bogdan Pasaniuc, Carmen Jerónimo, Rui Henrique, Matthew L. Freedman, Lodewyk F. A. Wessels, Nathan A. Lack, Andries M. Bergman, and Wilbert Zwart
    Nature Communications, Nov 2022
    HTML
  4. Genetic determinants of chromatin reveal prostate cancer risk mediated by context-dependent gene regulation
    Sylvan C. Baca, Cassandra Singler, Soumya Zacharia, Ji-Heui Seo, Tunc Morova, Faraz Hach, Yi Ding, Tommer Schwarz, Chia-Chi Flora Huang, Jacob Anderson, André P. Fay, Cynthia Kalita, Stefan Groha, Mark M. Pomerantz, Victoria Wang, Simon Linder, Christopher J. Sweeney, Wilbert Zwart, Nathan A. Lack, Bogdan Pasaniuc, David Y. Takeda, Alexander Gusev, and Matthew L. Freedman
    Nature Genetics, Sep 2022
    HTML
  5. EPIKOL, a chromatin-focused CRISPR/Cas9-based screening platform, to identify cancer-specific epigenetic vulnerabilities
    Ozlem Yedier-Bayram, Bengul Gokbayrak, Alisan Kayabolen, Ali Cenk Aksu, Ayse Derya Cavga, Ahmet Cingöz, Ezgi Yagmur Kala, Goktug Karabiyik, Rauf Günsay, Beril Esin, Tunc Morova, Firat Uyulur, Hamzah Syed, Martin Philpott, Adam P. Cribbs, Sonia H. Y. Kung, Nathan A. Lack, Tamer T. Onder, and Tugba Bagci-Onder
    Cell Death & Disease, Aug 2022
    HTML
  6. Epigenetic-focused CRISPR/Cas9 screen identifies ASH2L as a regulator of glioblastoma cell survival
    Ezgi Ozyerli-Goknar, Ezgi Yagmur Kala, Ali Cenk Aksu, Ipek Bulut, Ahmet Cingöz, Sheikh Nizamuddin, Martin Biniossek, Fidan Seker-Polat, Tunc Morova, Can Aztekin, Sonia H.A. Kung, Hamzah Syed, Nurcan Tuncbag, Mehmet Gonen, Martin Philpott, Adam P. Cribbs, Ceyda Acilan, Nathan A. Lack, Tamer T. Onder, H.T. Marc Timmers, and Tugba Bagci-Onder
    bioRxiv, Aug 2022
    HTML
  7. Protein Scaffold-Based Multimerization of Soluble ACE2 Efficiently Blocks SARS-CoV-2 Infection In Vitro and In Vivo
    Alisan Kayabolen, Ugur Akcan, Dogancan Ozturan, Hivda Ulbegi-Polat, Gizem Nur Sahin, Nareg Pinarbasi-Degirmenci, Canan Bayraktar, Gizem Soyler, Ehsan Sarayloo, Elif Nurtop, Berna Ozer, Gulen Guney-Esken, Tayfun Barlas, Ismail Selim Yildirim, Ozlem Dogan, Sercin Karahuseyinoglu, Nathan A. Lack, Mehmet Kaya, Cem Albayrak, Fusun Can, Ihsan Solaroglu, and Tugba Bagci-Onder
    Advanced Science, Jul 2022
    HTML
  8. Deep whole-genome ctDNA chronology of treatment-resistant prostate cancer
    Cameron Herberts, Matti Annala, Joonatan Sipola, Sarah W. S. Ng, Xinyi E. Chen, Anssi Nurminen, Olga V. Korhonen, Aslı D. Munzur, Kevin Beja, Elena Schönlau, Cecily Q. Bernales, Elie Ritch, Jack V. W. Bacon, Nathan A. Lack, Matti Nykter, Rahul Aggarwal, Eric J. Small, Martin E. Gleave, David A. Quigley, Felix Y. Feng, Kim N. Chi, and Alexander W. Wyatt and
    Nature, Jul 2022
    HTML
  9. Drug-Induced Epigenomic Plasticity Reprograms Circadian Rhythm Regulation to Drive Prostate Cancer toward Androgen Independence
    Simon Linder, Marlous Hoogstraat, Suzan Stelloo, Nils Eickhoff, Karianne Schuurman, Hilda Barros, Maartje Alkemade, Elise M. Bekers, Tesa M. Severson, Joyce Sanders, Chia-Chi Flora Huang, Tunc Morova, Umut Berkay Altintas, Liesbeth Hoekman, Yongsoo Kim, Sylvan C. Baca, Martin Sjöström, Anniek Zaalberg, Dorine C. Hintzen, Jeroen Jong, Roelof J.C. Kluin, Iris Rink, Claudia Giambartolomei, Ji-Heui Seo, Bogdan Pasaniuc, Maarten Altelaar, René H. Medema, Felix Y. Feng, Amina Zoubeidi, Matthew L. Freedman, Lodewyk F.A. Wessels, Lisa M. Butler, Nathan A. Lack, Henk Poel, Andries M. Bergman, and Wilbert Zwart
    Cancer Discovery, Jun 2022
    HTML
  10. Genome-wide CRISPR screen identifies PRC2 and KMT2D-COMPASS as regulators of distinct EMT trajectories that contribute differentially to metastasis
    Yun Zhang, Joana Liu Donaher, Sunny Das, Xin Li, Ferenc Reinhardt, Jordan A. Krall, Arthur W. Lambert, Prathapan Thiru, Heather R. Keys, Mehreen Khan, Matan Hofree, Molly M. Wilson, Ozlem Yedier-Bayram, Nathan A. Lack, Tamer T. Onder, Tugba Bagci-Onder, Michael Tyler, Itay Tirosh, Aviv Regev, Jacqueline A. Lees, and Robert A. Weinberg
    Nature Cell Biology, Apr 2022
    HTML
  11. Association of B7-H3 expression with racial ancestry, immune cell density, and androgen receptor activation in prostate cancer
    Adrianna A. Mendes, Jiayun Lu, Harsimar B. Kaur, Siqun L. Zheng, Jianfeng Xu, Jessica Hicks, Adam B. Weiner, Edward M. Schaeffer, Ashley E. Ross, Steven P. Balk, Mary-Ellen Taplin, Nathan A. Lack, Emirhan Tekoglu, Janielle P. Maynard, Angelo M. De Marzo, Emmanuel S. Antonarakis, Karen S. Sfanos, Corinne E. Joshu, Eugene Shenderov, and Tamara L. Lotan
    Cancer, Mar 2022
    HTML
  12. Androgen Receptor-Mediated Transcription in Prostate Cancer
    Dogancan Ozturan, Tunc Morova, and Nathan A. Lack
    Cells, Mar 2022
    HTML

2021

  1. Histologically benign PI-RADS 4 and 5 lesions contain cancer-associated epigenetic alterations
    Ceren Seref, Acar, Mert Kılıç, Metin Vural, Yeşim Sağlıcan, Hilal Saraç, Bilgen Coşkun, İnce, Tarık Esen, and Nathan A. Lack
    The Prostate, Oct 2021
    HTML
  2. Development of 2-(5, 6, 7-Trifluoro-1H-Indol-3-yl)-quinoline-5-carboxamide as a Potent, Selective, and Orally Available Inhibitor of Human Androgen Receptor Targeting Its Binding Function-3 for the Treatment of Castration-Resistant Prostate Cancer
    Eric Leblanc, Fuqiang Ban, Ayse Derya Cavga, Sam Lawn, Chia-Chi Flora Huang, Sankar Mohan, Matthew E. K. Chang, Mark R. Flory, Fariba Ghaidi, Shreyas Lingadahalli, Gang Chen, Ivan Pak Lok Yu, Hélène Morin, Nada Lallous, Martin E. Gleave, Hisham Mohammed, Robert N. Young, Paul S. Rennie, Nathan A. Lack, and Artem Cherkasov
    Journal of Medicinal Chemistry, Oct 2021
    HTML
  3. DNA binding alters ARv7 dimer interactions
    Fatma Ozgun, Zeynep Kaya, Tunc Morova, Bart Geverts, Tsion E. Abraham, Adriaan B. Houtsmuller, Martin E. Royen, and Nathan A. Lack
    Journal of Cell Science, Jul 2021
    HTML
  4. Development of an Androgen Receptor Inhibitor Targeting the N-Terminal Domain of Androgen Receptor for Treatment of Castration Resistant Prostate Cancer
    Fuqiang Ban, Eric Leblanc, Ayse Derya Cavga, Chia-Chi Flora Huang, Mark R. Flory, Fan Zhang, Matthew E. K. Chang, Hélène Morin, Nada Lallous, Kriti Singh, Martin E. Gleave, Hisham Mohammed, Paul S. Rennie, Nathan A. Lack, and Artem Cherkasov
    Cancers, Jul 2021
    HTML
  5. Functional mapping of androgen receptor enhancer activity
    Chia-Chi Flora Huang, Shreyas Lingadahalli, Tunc Morova, Dogancan Ozturan, Eugene Hu, Ivan Pak Lok Yu, Simon Linder, Marlous Hoogstraat, Suzan Stelloo, Funda Sar, Henk Poel, Umut Berkay Altintas, Mohammadali Saffarzadeh, Stephane Le Bihan, Brian McConeghy, Bengul Gokbayrak, Felix Y. Feng, Martin E. Gleave, Andries M. Bergman, Colin Collins, Faraz Hach, Wilbert Zwart, Eldon Emberly, and Nathan A. Lack
    Genome Biology, May 2021
    HTML

2020

  1. Androgen receptor-binding sites are highly mutated in prostate cancer
    Tunc Morova, Daniel R. McNeill, Nada Lallous, Mehmet Gönen, Kush Dalal, David M. Wilson, Attila Gürsoy, Keskin, and Nathan A. Lack
    Nature Communications, Feb 2020
    HTML

2019

  1. DeepCOP: deep learning-based approach to predict gene regulating effects of small molecules
    Godwin Woo, Michael Fernandez, Michael Hsing, Nathan A Lack, Ayse Derya Cavga, and Artem Cherkasov
    Bioinformatics, Aug 2019
    HTML
  2. Systematic characterization of chromatin modifying enzymes identifies KDM3B as a critical regulator in castration resistant prostate cancer
    Hilal Sarac, Tunc Morova, Elisabete Pires, James McCullagh, Anıl Kaplan, Ahmet Cingöz, Tugba Bagci-Onder, Tamer Önder, Akane Kawamura, and Nathan A. Lack
    Oncogene, Dec 2019
    HTML
  3. Androgen receptor plasticity and its implications for prostate cancer therapy
    Oliver Snow, Nada Lallous, Kriti Singh, Nathan Lack, Paul Rennie, and Artem Cherkasov
    Cancer Treatment Reviews, Dec 2019
    HTML
  4. ARv7 Represses Tumor-Suppressor Genes in Castration-Resistant Prostate Cancer
    Laura Cato, Jonas Tribolet-Hardy, Irene Lee, Jaice T. Rottenberg, Ilsa Coleman, Diana Melchers, René Houtman, Tengfei Xiao, Wei Li, Takuma Uo, Shihua Sun, Nane C. Kuznik, Bettina Göppert, Fatma Ozgun, Martin E. Royen, Adriaan B. Houtsmuller, Raga Vadhi, Prakash K. Rao, Lewyn Li, Steven P. Balk, Robert B. Den, Bruce J. Trock, R. Jeffrey Karnes, Robert B. Jenkins, Eric A. Klein, Elai Davicioni, Friederike J. Gruhl, Henry W. Long, X. Shirley Liu, Andrew C.B. Cato, Nathan A. Lack, Peter S. Nelson, Stephen R. Plymate, Anna C. Groner, and Myles Brown
    Cancer Cell, Mar 2019
    HTML

2018

  1. Small molecule-induced degradation of the full length and V7 truncated variant forms of human androgen receptor
    Kush Dalal, Helene Morin, Fuqiang Ban, Ashley Shepherd, Michael Fernandez, Kevin J. Tam, Huifang Li, Eric LeBlanc, Nathan Lack, Helge Prinz, Paul S. Rennie, and Artem Cherkasov
    European Journal of Medicinal Chemistry, Sep 2018
    HTML
  2. Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer
    David A. Quigley, Ha X. Dang, Shuang G. Zhao, Paul Lloyd, Rahul Aggarwal, Joshi J. Alumkal, Adam Foye, Vishal Kothari, Marc D. Perry, Adina M. Bailey, Denise Playdle, Travis J. Barnard, Li Zhang, Jin Zhang, Jack F. Youngren, Marcin P. Cieslik, Abhijit Parolia, Tomasz M. Beer, George Thomas, Kim N. Chi, Martin Gleave, Nathan A. Lack, Amina Zoubeidi, Robert E. Reiter, Matthew B. Rettig, Owen Witte, Charles J. Ryan, Lawrence Fong, Won Kim, Terence Friedlander, Jonathan Chou, Haolong Li, Rajdeep Das, Hui Li, Ruhollah Moussavi-Baygi, Hani Goodarzi, Luke A. Gilbert, Primo N. Lara, Christopher P. Evans, Theodore C. Goldstein, Joshua M. Stuart, Scott A. Tomlins, Daniel E. Spratt, R. Keira Cheetham, Donavan T. Cheng, Kyle Farh, Julian S. Gehring, Jörg Hakenberg, Arnold Liao, Philip G. Febbo, John Shon, Brad Sickler, Serafim Batzoglou, Karen E. Knudsen, Housheng H. He, Jiaoti Huang, Alexander W. Wyatt, Scott M. Dehm, Alan Ashworth, Arul M. Chinnaiyan, Christopher A. Maher, Eric J. Small, and Felix Y. Feng
    Cell, Jul 2018
    HTML
  3. Impact of the ST101 clone on fatality among patients with colistin-resistant Klebsiella pneumoniae infection
    Fusun Can, Sirin Menekse, Pelin Ispir, Nazlı Atac, Ozgur Albayrak, Tuana Demir, Doruk Can Karaaslan, Salih Nafiz Karahan, Mahir Kapmaz, Ozlem Kurt Azap, Funda Timurkaynak, Serap Simsek Yavuz, Seniha Basaran, Fugen Yoruk, Alpay Azap, Safiye Koculu, Nur Benzonana, Nathan A Lack, Mehmet Gönen, and Onder Ergonul
    Journal of Antimicrobial Chemotherapy, Feb 2018
    HTML

2017

  1. KDM2B, an H3K36-specific demethylase, regulates apoptotic response of GBM cells to TRAIL
    Ibrahim Cagri Kurt, Ilknur Sur, Ezgi Kaya, Ahmet Cingoz, Selena Kazancioglu, Zeynep Kahya, Omer Duhan Toparlak, Filiz Senbabaoglu, Zeynep Kaya, Ezgi Ozyerli, Sercin Karahüseyinoglu, Nathan A Lack, Zeynep H Gümüs, Tamer T Onder, and Tugba Bagci-Onder
    Cell Death & Disease, Jun 2017
    HTML
  2. Investigation of the mycobacterial enzyme HsaD as a potential novel target for anti-tubercular agents using a fragment-based drug design approach
    Ali Ryan, Elena Polycarpou, Nathan A Lack, Dimitrios Evangelopoulos, Christian Sieg, Alice Halman, Sanjib Bhakta, Olga Eleftheriadou, Timothy D McHugh, Sebastian Keany, Edward D Lowe, Romain Ballet, Areej Abuhammad, William R Jacobs, Alessio Ciulli, and Edith Sim
    British Journal of Pharmacology, May 2017
    HTML
  3. Pathogenic mycobacteria achieve cellular persistence by inhibiting the Niemann-Pick Type C disease cellular pathway
    Paul Fineran, Emyr Lloyd-Evans, Nathan A. Lack, Nick Platt, Lianne C. Davis, Anthony J. Morgan, Doris Höglinger, Raju Venkata V. Tatituri, Simon Clark, Ian M. Williams, Patricia Tynan, Nada Al Eisa, Evgeniya Nazarova, Ann Williams, Antony Galione, Daniel S. Ory, Gurdyal S. Besra, David G. Russell, Michael B. Brenner, Edith Sim, and Frances M. Platt
    Wellcome Open Research, Jun 2017
    HTML

2016

  1. Identification of Mitoxantrone as a TRAIL-sensitizing agent for Glioblastoma Multiforme
    Filiz Senbabaoglu, Ahmet Cingoz, Ezgi Kaya, Selena Kazancioglu, Nathan A. Lack, Ceyda Acilan, and Tugba Bagci-Onder
    Cancer Biology & Therapy, Mar 2016
    HTML
  2. Cytotoxicity and mitogenicity assays with real-time and label-free monitoring of human granulosa cells with an impedance-based signal processing technology intergrating micro-electronics and cell biology
    Ozgur Oktem, Gamze Bildik, Filiz Senbabaoglu, Nathan A. Lack, Nazli Akin, Feridun Yakar, Defne Urman, Yilmaz Guzel, Basak Balaban, Akira Iwase, and Bulent Urman
    Reproductive Toxicology, Apr 2016
    HTML

2015

  1. Determining the origin of synchronous multifocal bladder cancer by exome sequencing
    Omer Acar, Ezgi Özkurt, Gulfem Demir, Hilal Sarac, Can Alkan, Tarık Esen, Mehmet Somel, and Nathan A. Lack
    BMC Cancer, Nov 2015
    HTML
  2. Activating mutations of STAT5B and STAT3 in lymphomas derived from γδ-T or NK cells
    Can Küçük, Bei Jiang, Xiaozhou Hu, Wenyan Zhang, John K. C. Chan, Wenming Xiao, Nathan Lack, Can Alkan, John C. Williams, Kendra N. Avery, Pınar Kavak, Anna Scuto, Emel Sen, Philippe Gaulard, Lou Staudt, Javeed Iqbal, Weiwei Zhang, Adam Cornish, Qiang Gong, Qunpei Yang, Hong Sun, Francesco d’Amore, Sirpa Leppä, Weiping Liu, Kai Fu, Laurence Leval, Timothy McKeithan, and Wing C. Chan
    Nature Communications, Jan 2015
    HTML

2014

  1. Characterisation of a putative AraC transcriptional regulator from Mycobacterium smegmatis
    Dimitrios Evangelopoulos, Antima Gupta, Nathan A. Lack, Arundhati Maitra, Annemieke M.C. Bokum, Sharon Kendall, Edith Sim, and Sanjib Bhakta
    Tuberculosis, Dec 2014
    HTML
  2. Deletion of conserved protein phosphatases reverses defects associated with mitochondrial DNA damage in Saccharomyces cerevisiae
    Görkem Garipler, Nebibe Mutlu, Nathan A. Lack, and Cory D. Dunn
    Proceedings of the National Academy of Sciences, Jan 2014
    HTML

2013

  1. Characterization of a New Class of Androgen Receptor Antagonists with Potential Therapeutic Application in Advanced Prostate Cancer
    Huifang Li, Mohamed D.H. Hassona, Nathan A. Lack, Peter Axerio-Cilies, Eric Leblanc, Peyman Tavassoli, Natalia Kanaan, Kate Frewin, Kriti Singh, Hans Adomat, Konrad J. Böhm, Helge Prinz, Emma Tomlinson Guns, Paul S. Rennie, and Artem Cherkasov
    Molecular Cancer Therapeutics, Nov 2013
    HTML
  2. New Therapeutics to Treat Castrate-Resistant Prostate Cancer
    Omer Acar, Tarık Esen, and Nathan A. Lack
    The Scientific World Journal, Nov 2013
    HTML
  3. Genetic variants of MARCO are associated with susceptibility to pulmonary tuberculosis in a Gambian population
    Dawn ME Bowdish, Kaori Sakamoto, Nathan A Lack, Philip C Hill, Giorgio Sirugo, Melanie J Newport, Siamon Gordon, Adrian VS Hill, and Fredrick O Vannberg
    BMC Medical Genetics, Apr 2013
    HTML
  4. Targeting the Binding Function 3 (BF3) Site of the Androgen Receptor Through Virtual Screening. 2. Development of 2-((2-phenoxyethyl) thio)-1H-benzimidazole Derivatives
    Ravi Shashi Nayana Munuganti, Eric Leblanc, Peter Axerio-Cilies, Christophe Labriere, Kate Frewin, Kriti Singh, Mohamed D. H. Hassona, Nathan A. Lack, Huifang Li, Fuqiang Ban, Emma Tomlinson Guns, Robert Young, Paul S. Rennie, and Artem Cherkasov
    Journal of Medicinal Chemistry, Jan 2013
    HTML

2012

  1. Cloning, expression, purification, crystallization and X-ray analysis of inositol monophosphatase from Mus musculus and Homo sapiens
    Nisha Singh, Amy C. Halliday, Matthew Knight, Nathan A. Lack, Edward Lowe, and Grant C. Churchill
    Acta Crystallographica Section F Structural Biology and Crystallization Communications, Sep 2012
    HTML
  2. A CD74-dependent MHC class I endolysosomal cross-presentation pathway
    Genc Basha, Kyla Omilusik, Ana Chavez-Steenbock, Anna T Reinicke, Nathan Lack, Kyung Bok Choi, and Wilfred A Jefferies
    Nature Immunology, Feb 2012
    HTML

2011

  1. Targeting the Binding Function 3 (BF3) Site of the Human Androgen Receptor through Virtual Screening.
    Nathan A. Lack, Peter Axerio-Cilies, Peyman Tavassoli, Frank Q. Han, Ka Hong Chan, Clementine Feau, Eric LeBlanc, Emma Tomlinson Guns, R. Kiplin Guy, Paul S. Rennie, and Artem Cherkasov
    Journal of Medicinal Chemistry, Nov 2011
    HTML
  2. Inhibitors of Androgen Receptor Activation Function-2 (AF2) Site Identified through Virtual Screening
    Peter Axerio-Cilies, Nathan A. Lack, M. Ravi Shashi Nayana, Ka Hong Chan, Anthony Yeung, Eric Leblanc, Emma S. Tomlinson Guns, Paul S. Rennie, and Artem Cherkasov
    Journal of Medicinal Chemistry, Aug 2011
    HTML
  3. Antiandrogenic and growth inhibitory effects of ring-substituted analogs of 3, 3’-diindolylmethane (Ring-DIMs) in hormone-responsive LNCaP human prostate cancer cells
    Khalil Abdelbaqi, Nathan Lack, Emma Tomlinson Guns, Leela Kotha, Stephen Safe, and J. Thomas Sanderson
    The Prostate, Feb 2011
    HTML

2010

  1. Characterization of a Carbon-Carbon Hydrolase from Mycobacterium tuberculosis Involved in Cholesterol Metabolism
    Nathan A. Lack, Katherine C. Yam, Edward D. Lowe, Geoff P. Horsman, Robin L. Owen, Edith Sim, and Lindsay D. Eltis
    Journal of Biological Chemistry, Jan 2010
    HTML

2009

  1. Multiple routes of complement activation by Mycobacterium bovis BCG
    Maria V. Carroll, Nathan Lack, Edith Sim, Anders Krarup, and Robert B. Sim
    Molecular Immunology, Oct 2009
    HTML
  2. Temperature stability of proteins essential for the intracellular survival of Mycobacterium tuberculosis
    Nathan A. Lack, Akane Kawamura, Elizabeth Fullam, Nicola Laurieri, Stacey Beard, Angela J. Russell, Dimitrios Evangelopoulos, Isaac Westwood, and Edith Sim
    Biochemical Journal, Feb 2009
    HTML

2008

  1. Arylamine N-acetyltransferases: Structural and functional implications of polymorphisms
    Edith Sim, Nathan Lack, Chan-Ju Wang, Hilary Long, Isaac Westwood, Elizabeth Fullam, and Akane Kawamura
    Toxicology, Dec 2008
    HTML
  2. Arylamine N-Acetyltransferases in Mycobacteria
    Edith Sim, James Sandy, Dimitrios Evangelopoulos, Elizabeth Fullam, Sanjib Bhakta, Isaac Westwood, Anna Krylova, Nathan Lack, and Martin Noble
    Current Drug Metabolism, Jul 2008
    HTML

2007

  1. Structure of HsaD, a steroid-degrading hydrolase, from Mycobacterium tuberculosis
    Nathan Lack, Edward D. Lowe, Jie Liu, Lindsay D. Eltis, Martin E. M. Noble, Edith Sim, and Isaac M. Westwood
    Acta Crystallographica Section F Structural Biology and Crystallization Communications, Dec 2007
    HTML
  2. Ocular defects associated with a null mutation in the mouse arylamine N-acetyltransferase 2 gene
    Larissa Wakefield, Hilary Long, Nathan Lack, and Edith Sim
    Mammalian Genome, Apr 2007
    HTML

2005

  1. A Pharmacokinetic-pharmacodynamic Model for the Mobilization of CD34+ Hematopoietic Progenitor Cells by AMD3100
    N. A. Lack, B. Green, D. C. Dale, G. B. Calandra, H. Lee, R. T. MacFarland, K. Badel, W. C. Liles, and G. Bridger
    Clinical Pharmacology & Therapeutics, Apr 2005
    HTML